MX2017015927A - Fragmentos mutantes de proteina ras. - Google Patents

Fragmentos mutantes de proteina ras.

Info

Publication number
MX2017015927A
MX2017015927A MX2017015927A MX2017015927A MX2017015927A MX 2017015927 A MX2017015927 A MX 2017015927A MX 2017015927 A MX2017015927 A MX 2017015927A MX 2017015927 A MX2017015927 A MX 2017015927A MX 2017015927 A MX2017015927 A MX 2017015927A
Authority
MX
Mexico
Prior art keywords
ras protein
mutated
region
peptide
mutated fragments
Prior art date
Application number
MX2017015927A
Other languages
English (en)
Inventor
Amund Eriksen Jon
Original Assignee
Targovax Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targovax Asa filed Critical Targovax Asa
Publication of MX2017015927A publication Critical patent/MX2017015927A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describe un péptido adecuado para producir una respuesta inmune. El péptido corresponde a un fragmento de la proteína RAS y comprende una región de 8 aminoácidos la cual incluye una posición mutante de la proteína RAS. La región tiene al menos 6 residuos de aminoácidos, diferentes a los de la posición mutante, los cuales son idénticos a los de la región correspondiente de la proteína RAS. El péptido tiene una mutación puntual en el aminoácido que corresponde a la posición mutante y la posición mutante es la posición 146 o 117 de la proteína RAS.
MX2017015927A 2015-06-16 2016-06-16 Fragmentos mutantes de proteina ras. MX2017015927A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15172418 2015-06-16
PCT/EP2016/063920 WO2016202937A1 (en) 2015-06-16 2016-06-16 Mutated fragments of the ras protein

Publications (1)

Publication Number Publication Date
MX2017015927A true MX2017015927A (es) 2018-04-18

Family

ID=53404437

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015927A MX2017015927A (es) 2015-06-16 2016-06-16 Fragmentos mutantes de proteina ras.

Country Status (14)

Country Link
US (1) US20190374628A1 (es)
EP (1) EP3310808A1 (es)
JP (1) JP2018518177A (es)
KR (1) KR20180021072A (es)
CN (1) CN107922472A (es)
AU (1) AU2016280770A1 (es)
BR (1) BR112017025728A2 (es)
CA (1) CA2989373A1 (es)
CL (1) CL2017003228A1 (es)
HK (1) HK1248714A1 (es)
IL (1) IL256077A (es)
MX (1) MX2017015927A (es)
RU (1) RU2018101225A (es)
WO (1) WO2016202937A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018214556A1 (en) * 2017-02-01 2019-08-15 Modernatx, Inc. Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides
US11771749B2 (en) * 2017-02-03 2023-10-03 The Medical College Of Wisconsin, Inc. KRAS peptide vaccine compositions and method of use
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
US20210340201A1 (en) * 2018-08-22 2021-11-04 Fred Hutchinson Cancer Research Center Immunotherapy targeting kras or her2 antigens
CN110205298B (zh) * 2019-06-11 2020-05-15 焦顺昌 一种靶向kras突变的异体抗原递呈细胞、构建方法及肠癌特异性ctl细胞的制备方法
CN110184238A (zh) * 2019-06-11 2019-08-30 北京鼎成肽源生物技术有限公司 一种靶向kras多发突变肿瘤的特异性ctl细胞的制备方法及应用
CN110172480B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 双抗原表位融合基因重组慢病毒载体、抗原提呈细胞和ctl细胞及其构建方法和应用
US20220378887A1 (en) * 2019-11-07 2022-12-01 Genoimmune Therapeutics Co., Ltd. Tumor immunotherapy polypeptide and application thereof
US20240123070A1 (en) * 2021-02-10 2024-04-18 Shanghai GenBase Biotechnology Co., Ltd. Epitope peptide of ras g13d mutant and t cell receptor recognizing ras g13d mutant
WO2024147556A1 (ko) * 2023-01-05 2024-07-11 의료법인 명지의료재단 K-ras 돌연변이 다중 항원결정기 폴리펩타이드를 유효성분으로 포함하는 항암 백신용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
CA2647102A1 (en) * 2006-03-27 2007-11-22 Globeimmune, Inc. Ras mutation and compositions and methods related thereto

Also Published As

Publication number Publication date
CN107922472A (zh) 2018-04-17
BR112017025728A2 (pt) 2018-08-07
RU2018101225A (ru) 2019-07-16
IL256077A (en) 2018-01-31
JP2018518177A (ja) 2018-07-12
US20190374628A1 (en) 2019-12-12
EP3310808A1 (en) 2018-04-25
AU2016280770A1 (en) 2018-01-04
CL2017003228A1 (es) 2018-07-13
KR20180021072A (ko) 2018-02-28
WO2016202937A1 (en) 2016-12-22
HK1248714A1 (zh) 2018-10-19
CA2989373A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
MX2017015927A (es) Fragmentos mutantes de proteina ras.
MX2016007429A (es) Mezcla de peptidos.
SA522433260B1 (ar) Rsv f طافرات بروتين
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
MX2019010887A (es) Proteinas inmunomoduladoras de cb80 variante y usos de estas.
UA120917C2 (uk) Химерний білок фактора viii та його застосування
MX2023014077A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
EP3936141A3 (en) Anti-senescence compounds and uses thereof
MX2018012550A (es) Composiciones y metodos para la deteccion de proteinas de celulas huesped.
EP4219540A3 (en) Ctla-4 variant immunomodulatory proteins and uses thereof
EP4374913A3 (en) Novel human serum albumin mutant
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
MY195726A (en) Steviol Glycoside Transport
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
WO2018132821A3 (en) Elastomeric proteins
MX2018014966A (es) Peptidos monolipidados resistentes a proteasas.
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
NZ744289A (en) Composition containing amino acids
MX2015009867A (es) Mutantes del factor x.
SG10201806532RA (en) Proteins targeting orthologs
WO2016205522A3 (en) Antibodies recognizing phosphorylation at specific amino acid residues of transactive response dna-binding protein 43
BR112017000146A2 (pt) micro-organismo recombinante do gênero escherichia produzindo ácido quinolínico, e método de produção de ácido quinolínico